Published Feb. 8, 2013
Fluor Corp. said Thursday it began early construction management services at Baxter International Inc.’s new biotechnology facility in Georgia.
The project is expected to employ around 2,200 people at its construction peak. Fluor’s Greenville office is providing support.
The Baxter facility in Covington, Ga., about 45 miles southeast of Atlanta, will manufacture immunoglobulin therapy products for patients with immune deficiencies and albumin. These products are primarily used as plasma-volume replacement therapy in critical care, trauma and burn patients.
The $1 billion campus, which will include multiple manufacturing facilities, laboratories, warehouses and other space, is expected to employ 1,500 people and become fully operational in 2018.
“Fluor is proud that our project and construction management services will help Baxter make this facility a reality to create therapies to treat a number of chronic and acute conditions, including immune deficiencies and critical care patients around the world,” said Steve Dobbs, president of Fluor’s Industrial and Infrastructure Business Group, in a news release.